|Bid||107.90 x 800|
|Ask||117.68 x 1400|
|Day's Range||113.90 - 117.75|
|52 Week Range||46.00 - 124.01|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||131.77|
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
Shareholders in Acceleron Pharma Inc. (NASDAQ:XLRN) may be thrilled to learn that the analysts have just delivered a...
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented a set of preliminary interim data from the ongoing SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).